TRPV1 and obesity due to melanocortin 4 receptor deficiency: If this conclusion is accurate, then it would indicate a possible target for future research on chronic treatment with TRPV1 agonists in the diabetic and obesity conditions, evaluating whether these agonists could attenuate or prevent vascular dysfunction.